Terms: = Prostate cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Staging
13 results:
1. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
2. Nanotechnology-based approaches for effective detection of tumor markers: A comprehensive state-of-the-art review.
Laraib U; Sargazi S; Rahdar A; Khatami M; Pandey S
Int J Biol Macromol; 2022 Jan; 195():356-383. PubMed ID: 34920057
[TBL] [Abstract] [Full Text] [Related]
3. Down Regulation of KAI1/CD82 in Lymph Node Positive and Advanced T-Stage Group in Breast cancer Patients.
Krishna Latha T; Verma A; Thakur GK; Banerjee B; Kaur N; Singh UR; Sharma S
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3321-3329. PubMed ID: 31759355
[TBL] [Abstract] [Full Text] [Related]
4. Small cell cancer of the prostate.
Dixit S; Coup A; Hunt C; Coombs L
Urology; 2012 Nov; 80(5):e58-60. PubMed ID: 23107415
[TBL] [Abstract] [Full Text] [Related]
5. Back to the embryonic stage: Nodal as a biomarker for breast cancer progression.
Bar-Eli M
Breast Cancer Res; 2012 May; 14(3):105. PubMed ID: 22643182
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic value of her-2/neu and clinicopathologic factors for evaluating progression and disease-specific death in Chinese men with prostate cancer.
Zhang YF; Guan YB; Yang B; Wu HY; Dai YT; Zhang SJ; Wang JP; Anoopkumar-Dukie S; Davey AK; Sun ZY
Chin Med J (Engl); 2011 Dec; 124(24):4345-9. PubMed ID: 22340411
[TBL] [Abstract] [Full Text] [Related]
7. Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer.
Bouchelouche K; Capala J; Oehr P
Curr Opin Oncol; 2009 Sep; 21(5):469-74. PubMed ID: 19535981
[TBL] [Abstract] [Full Text] [Related]
8. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.
Vuky J; Porter C; Isacson C; Vaughan M; Kozlowski P; Picozzi V; Corman J
Cancer; 2009 Feb; 115(4):784-91. PubMed ID: 19130458
[TBL] [Abstract] [Full Text] [Related]
9. prostate-derived Ets transcription factor overexpression is associated with nodal metastasis and hormone receptor positivity in invasive breast cancer.
Turcotte S; Forget MA; Beauseigle D; Nassif E; Lapointe R
Neoplasia; 2007 Oct; 9(10):788-96. PubMed ID: 17971898
[TBL] [Abstract] [Full Text] [Related]
10. Preoperative plasma her2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.
Shariat SF; Bensalah K; Karam JA; Roehrborn CG; Gallina A; Lotan Y; Slawin KM; Karakiewicz PI
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5377-84. PubMed ID: 17875766
[TBL] [Abstract] [Full Text] [Related]
11. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice.
Salminen E; Hogg A; Binns D; Frydenberg M; Hicks R
Acta Oncol; 2002; 41(5):425-9. PubMed ID: 12442917
[TBL] [Abstract] [Full Text] [Related]
12. Aneusomy of chromosomes 7, 8, and 17 and amplification of her-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray.
Skacel M; Ormsby AH; Pettay JD; Tsiftsakis EK; Liou LS; Klein EA; Levin HS; Zippe CD; Tubbs RR
Hum Pathol; 2001 Dec; 32(12):1392-7. PubMed ID: 11774175
[TBL] [Abstract] [Full Text] [Related]
13. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer.
Oesterling JE; Martin SK; Bergstralh EJ; Lowe FC
JAMA; 1993 Jan; 269(1):57-60. PubMed ID: 7677962
[TBL] [Abstract] [Full Text] [Related]
